Journal article
Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2
Abstract
Vaccination using the adenoviral vector COVID-19 vaccine ChAdOx1 nCoV-19 (AstraZeneca) has been associated with rare vaccine-induced immune thrombotic thrombocytopenia (VITT). Affected patients test strongly positive in platelet factor 4 (PF4)/polyanion enzyme immunoassays (EIAs), and serum-induced platelet activation is maximal in the presence of PF4. We determined the frequency of anti-PF4/polyanion antibodies in healthy vaccinees and …
Authors
Thiele T; Ulm L; Holtfreter S; Schönborn L; Kuhn SO; Scheer C; Warkentin TE; Bröker BM; Becker K; Aurich K
Journal
Blood, Vol. 138, No. 4, pp. 299–303
Publisher
American Society of Hematology
Publication Date
July 29, 2021
DOI
10.1182/blood.2021012217
ISSN
0006-4971
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdultAsymptomatic DiseasesAutoantibodiesBNT162 VaccineCOVID-19COVID-19 VaccinesChAdOx1 nCoV-19FemaleHealth PersonnelHumansImmunoenzyme TechniquesImmunoglobulin GMaleMiddle AgedPlatelet ActivationPlatelet Factor 4PolyelectrolytesPurpura, Thrombotic ThrombocytopenicSeroconversionThrombophiliaVaccination